Skip to Main Content
Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 2009, Issue 1
December 4 2009
Issue Cover

Table of Contents

Ham-Wasserman Lecture

Darwin and evolutionary tales in leukemia
Mel Greaves
View Articletitled, Darwin and evolutionary tales in leukemia

Introduction to Surrogates and Evidence-based Mini-Reviews

Introduction to surrogates and evidence-based mini-reviews
Mark A. Crowther
View Articletitled, Introduction to surrogates and evidence-based mini-reviews

Thalassemias

Newborn screening for non-sickling hemoglobinopathies
Carolyn C. Hoppe
View Articletitled, Newborn screening for non-sickling hemoglobinopathies
Hb H disease: clinical course and disease modifiers
Suthat Fucharoen,Vip Viprakasit
View Articletitled, Hb H disease: clinical course and disease modifiers
Alpha thalassemia major—new mutations, intrauterine management, and outcomes
Elliott P. Vichinsky
View Articletitled, Alpha thalassemia major—new mutations, intrauterine management, and outcomes

Sickle Cell Disease

Asthma and sickle cell disease: two distinct diseases or part of the same process?
Joshua J. Field,Michael R. DeBaun
View Articletitled, Asthma and sickle cell disease: two distinct diseases or part of the same process?
Novel therapies in sickle cell disease
Kenneth I. Ataga
View Articletitled, Novel therapies in sickle cell disease
Advances in the use of hydroxyurea
Russell E. Ware,Banu Aygun
View Articletitled, Advances in the use of hydroxyurea

Hemolytic Anemias

Drug-induced immune hemolytic anemia
George Garratty
View Articletitled, Drug-induced immune hemolytic anemia
Immune hemolytic anemia—selected topics
Philip C. Hoffman
View Articletitled, Immune hemolytic anemia—selected topics
Malaria, erythrocytic infection, and anemia
Kasturi Haldar,Narla Mohandas
View Articletitled, Malaria, erythrocytic infection, and anemia

Mucocutaneous Bleeding Disorders

Factor XI deficiency—resolving the enigma?
Paula H. B. Bolton-Maggs
View Articletitled, Factor XI deficiency—resolving the enigma?
Low von Willebrand factor: sometimes a risk factor and sometimes a disease
J. Evan Sadler
View Articletitled, Low von Willebrand factor: sometimes a risk factor and sometimes a disease
Optimizing treatment of von Willebrand disease by using phenotypic and molecular data
Francesco Rodeghiero,Giancarlo Castaman,Alberto Tosetto
View Articletitled, Optimizing treatment of von Willebrand disease by using phenotypic and molecular data

Primary Immunodeficiencies: The Frequent Association with Cytopenias

Hemophagocytic lymphohistiocytosis (HLH) and related disorders
Alexandra H. Filipovich
View Articletitled, Hemophagocytic lymphohistiocytosis (HLH) and related disorders
New insights into the biology of Wiskott-Aldrich syndrome (WAS)
Adrian J. Thrasher
View Articletitled, New insights into the biology of Wiskott-Aldrich syndrome (WAS)
Primary immunodeficiencies (PIDs) presenting with cytopenias
Luigi D. Notarangelo
View Articletitled, Primary immunodeficiencies (PIDs) presenting with cytopenias

Platelets: Too Many, Too Few

Determinants of platelet number and regulation of thrombopoiesis
Kenneth Kaushansky
View Articletitled, Determinants of platelet number and regulation of thrombopoiesis
Drug-induced thrombocytopenia: pathogenesis, evaluation, and management
James N. George,Richard H. Aster
View Articletitled, Drug-induced thrombocytopenia: pathogenesis, evaluation, and management
Thrombocytosis
Radek C. Skoda
View Articletitled, Thrombocytosis

Transfusion Medicine

Transfusion in the age of molecular diagnostics
Marion E. Reid
View Articletitled, Transfusion in the age of molecular diagnostics
Molecular biology of the Rh system: clinical considerations for transfusion in sickle cell disease
Stella T. Chou,Connie M. Westhoff
View Articletitled, Molecular biology of the Rh system: clinical considerations for transfusion in sickle cell disease
Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn
Davor Brinc,Alan H. Lazarus
View Articletitled, Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn

Iron Overload

Hereditary hemochromatosis: insights from the Hemochromatosis and Iron Overload Screening (HEIRS) Study
Gordon D. McLaren,Victor R. Gordeuk
View Articletitled, Hereditary hemochromatosis: insights from the Hemochromatosis and Iron Overload Screening (HEIRS) Study
Molecular mechanisms of normal iron homeostasis
An-Sheng Zhang,Caroline A. Enns
View Articletitled, Molecular mechanisms of normal iron homeostasis
Non-invasive assessment of tissue iron overload
Roland Fischer,Paul R. Harmatz
View Articletitled, Non-invasive assessment of tissue iron overload

Between a Rock and a Hard Place: Thrombotic Risk in the Thrombocytopenic Patient (Consultative Hematology)

Heparin-induced thrombocytopenia: when a low platelet count is a mandate for anticoagulation
Thomas L. Ortel
View Articletitled, Heparin-induced thrombocytopenia: when a low platelet count is a mandate for anticoagulation
Antiphospholipid antibody syndrome
Wendy Lim
View Articletitled, Antiphospholipid antibody syndrome
Thrombocytopenia and thrombosis in disseminated intravascular coagulation (DIC)
Craig S. Kitchens
View Articletitled, Thrombocytopenia and thrombosis in disseminated intravascular coagulation (DIC)
ASH evidence-based guidelines: should asymptomatic patients with antiphospholipid antibodies receive primary prophylaxis to prevent thrombosis?
Ara Metjian,Wendy Lim
View Articletitled, ASH evidence-based guidelines: should asymptomatic patients with antiphospholipid antibodies receive primary prophylaxis to prevent thrombosis?
ASH evidence-based guidelines: is the IgG-specific anti-PF4/heparin ELISA superior to the polyspecific ELISA in the laboratory diagnosis of HIT?
Adam Cuker,Thomas L. Ortel
View Articletitled, ASH evidence-based guidelines: is the IgG-specific anti-PF4/heparin ELISA superior to the polyspecific ELISA in the laboratory diagnosis of HIT?

Venous Versus Arterial Thrombosis

Pathogenesis of thrombosis
Bruce Furie
View Articletitled, Pathogenesis of thrombosis
Risk of future arterial cardiovascular events in patients with idiopathic venous thromboembolism
David Green
View Articletitled, Risk of future arterial cardiovascular events in patients with idiopathic venous thromboembolism
Antiplatelet agents
David Varon,Galia Spectre
View Articletitled, Antiplatelet agents
ASH evidence-based guidelines: statins in the prevention of venous thromboembolism
Natalie S. Evans,David Green
View Articletitled, ASH evidence-based guidelines: statins in the prevention of venous thromboembolism

Thrombotic Challenges Beyond Hematology

Pregnancy-associated thrombosis
Andra H. James
View Articletitled, Pregnancy-associated thrombosis
Prevention of venous thromboembolism: consensus, controversies, and challenges
Rita Selby,William Geerts
View Articletitled, Prevention of venous thromboembolism: consensus, controversies, and challenges
Evaluation and management of stroke
Brett L. Cucchiara
View Articletitled, Evaluation and management of stroke
ASH evidence-based guidelines: what is the role of inferior vena cava filters in the perioperative prevention of venous thromboembolism in bariatric surgery patients?
Anita Rajasekhar,Mark A. Crowther
View Articletitled, ASH evidence-based guidelines: what is the role of inferior vena cava filters in the perioperative prevention of venous thromboembolism in bariatric surgery patients?

Integrating Complementary Medicine into Hematology Care

Integrative therapies for children with hematological malignancies
Kara M. Kelly
View Articletitled, Integrative therapies for children with hematological malignancies
Supplements for immune enhancement in hematologic malignancies
Daniel Man-Yuen Sze,Godfrey Chi-Fung Chan
View Articletitled, Supplements for immune enhancement in hematologic malignancies
The bridge between patient and doctor: the shift from CAM to integrative medicine
Volker Diehl
View Articletitled, The bridge between patient and doctor: the shift from CAM to integrative medicine

Bone Marrow Failure

Clinical approach to marrow failure
Akiko Shimamura
View Articletitled, Clinical approach to marrow failure
Telomeres and marrow failure
Rodrigo T. Calado
View Articletitled, Telomeres and marrow failure
Congenital neutropenia
Christoph Klein
View Articletitled, Congenital neutropenia

Acute Lymphoblastic Leukemia

The role of NOTCH1 signaling in T-ALL
Adolfo A. Ferrando
View Articletitled, The role of NOTCH1 signaling in T-ALL
Evolving paradigms in the therapy of Philadelphia chromosome–negative acute lymphoblastic leukemia in adults
Mark R. Litzow
View Articletitled, Evolving paradigms in the therapy of Philadelphia chromosome–negative acute lymphoblastic leukemia in adults
Management of Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL)
Oliver G. Ottmann,Heike Pfeifer
View Articletitled, Management of Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph<sup>+</sup> ALL)

Acute Myeloid Leukemia

Independent prognostic factors for AML outcome
David Grimwade,Robert K. Hills
View Articletitled, Independent prognostic factors for AML outcome
Optimal induction and post-remission therapy for AML in first remission
Jacob M. Rowe
View Articletitled, Optimal induction and post-remission therapy for AML in first remission
What is the role of reduced-intensity transplantation in the treatment of older patients with AML?
Stephen J. Forman
View Articletitled, What is the role of reduced-intensity transplantation in the treatment of older patients with AML?
ASH evidence-based guidelines: is there a role for second allogeneic transplant after relapse?
Monica S. Thakar,Stephen J. Forman
View Articletitled, ASH evidence-based guidelines: is there a role for second allogeneic transplant after relapse?

Chronic Lymphocytic Leukemia

Predicting clinical outcome in CLL: how and why
Tait D. Shanafelt
View Articletitled, Predicting clinical outcome in CLL: how and why
Monoclonal B-cell lymphocytosis
Andy C. Rawstron
View Articletitled, Monoclonal B-cell lymphocytosis
State-of-the-art treatment of chronic lymphocytic leukemia
Michael Hallek
View Articletitled, State-of-the-art treatment of chronic lymphocytic leukemia

Chronic Myeloid Leukemia: After a Decade of Imatinib

Initial treatment for patients with CML
John M. Goldman
View Articletitled, Initial treatment for patients with CML
Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance
Dale Bixby,Moshe Talpaz
View Articletitled, Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance
Monitoring disease response to tyrosine kinase inhibitor therapy in CML
Timothy P. Hughes,Susan Branford
View Articletitled, Monitoring disease response to tyrosine kinase inhibitor therapy in CML

Hodgkin Lymphoma

Molecular biology of Hodgkin lymphoma
Ralf Küppers
View Articletitled, Molecular biology of Hodgkin lymphoma
Standard therapy of advanced Hodgkin lymphoma
John Kuruvilla
View Articletitled, Standard therapy of advanced Hodgkin lymphoma
Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma
Anas Younes
View Articletitled, Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma

Non-Hodgkin Lymphoma

The 2008 WHO classification of lymphomas: implications for clinical practice and translational research
Elaine S. Jaffe
View Articletitled, The 2008 WHO classification of lymphomas: implications for clinical practice and translational research
The incidence, natural history, biology, and treatment of transformed lymphomas
Steven H. Bernstein,W. Richard Burack
View Articletitled, The incidence, natural history, biology, and treatment of transformed lymphomas
Current treatment standards and emerging strategies in mantle cell lymphoma
Martin Dreyling,Wolfgang Hiddemann,for The European MCL Network
View Articletitled, Current treatment standards and emerging strategies in mantle cell lymphoma

Multiple Myeloma

How to treat a newly diagnosed young patient with multiple myeloma
Jesús F. San-Miguel,María-Victoria Mateos
View Articletitled, How to treat a newly diagnosed young patient with multiple myeloma
How to treat elderly patients with multiple myeloma: combination of therapy or sequencing
Antonio Palumbo,Francesca Gay
View Articletitled, How to treat elderly patients with multiple myeloma: combination of therapy or sequencing
Novel therapies for relapsed myeloma
A. Keith Stewart
View Articletitled, Novel therapies for relapsed myeloma
ASH evidence-based guidelines: what is the role of maintenance therapy in the treatment of multiple myeloma?
Irene M. Ghobrial,A. Keith Stewart
View Articletitled, ASH evidence-based guidelines: what is the role of maintenance therapy in the treatment of multiple myeloma?

Allogeneic Hematopoietic Cell Transplantation: Focus on Lymphoproliferative Disorders

Transplantation in adult ALL
Anthony H. Goldstone,Jacob M. Rowe
View Articletitled, Transplantation in adult ALL
Allotransplantation for chronic lymphocytic leukemia
Peter Dreger
View Articletitled, Allotransplantation for chronic lymphocytic leukemia
Allogeneic stem cell transplantation in follicular lymphoma: recent progress and controversy
Koen van Besien
View Articletitled, Allogeneic stem cell transplantation in follicular lymphoma: recent progress and controversy

Myeloproliferative Disorders

Pathogenesis and management of essential thrombocythemia
Philip A. Beer,Anthony R. Green
View Articletitled, Pathogenesis and management of essential thrombocythemia
Idiopathic erythrocytosis: a disappearing entity
Mary Frances McMullin
View Articletitled, Idiopathic erythrocytosis: a disappearing entity
Therapeutic potential of JAK2 inhibitors
Srdan Verstovsek
View Articletitled, Therapeutic potential of JAK2 inhibitors

Myelodysplastic Syndromes

The changing classification of myelodysplastic syndromes: what’s in a name?
David P. Steensma
View Articletitled, The changing classification of myelodysplastic syndromes: what’s in a name?
Treatment of MDS: something old, something new, something borrowed…
Mikkael A. Sekeres
View Articletitled, Treatment of MDS: something old, something new, something borrowed…
Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?
Heather A. Leitch,Linda M. Vickars
View Articletitled, Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?

Newer Progress in Gene Therapy

Overview of gene therapy clinical progress including cancer treatment with gene-modified T cells
Malcolm K. Brenner,Fatma V. Okur
View Articletitled, Overview of gene therapy clinical progress including cancer treatment with gene-modified T cells
Ten years of gene therapy for primary immune deficiencies
Alessandro Aiuti,Maria Grazia Roncarolo
View Articletitled, Ten years of gene therapy for primary immune deficiencies
Hematopoietic stem cell gene transfer for the treatment of hemoglobin disorders
Derek A. Persons
View Articletitled, Hematopoietic stem cell gene transfer for the treatment of hemoglobin disorders

Nanotechnology for Hematology

Application of semiconductor and metal nanostructures in biology and medicine
Carl Walkey,Edward A. Sykes,Warren C. W. Chan
View Articletitled, Application of semiconductor and metal nanostructures in biology and medicine
Dendrimer-based nanoparticles for cancer therapy
James R. Baker, Jr.
View Articletitled, Dendrimer-based nanoparticles for cancer therapy
Imaging circulating cells and lymphoid tissues with iron oxide nanoparticles
Andrew Elias,Andrew Tsourkas
View Articletitled, Imaging circulating cells and lymphoid tissues with iron oxide nanoparticles

Junior-Faculty Development: Pursuing an Academic Job, Promotion, and Tenure 101

Finding the right academic job
Irene M. Ghobrial,Jacob P. Laubach,Robert J. Soiffer
View Articletitled, Finding the right academic job
The academic job offer: what to expect and how to negotiate
Andrew I. Schafer
View Articletitled, The academic job offer: what to expect and how to negotiate
Academic promotion and tenure: a user’s guide for junior faculty members
George R. Buchanan
View Articletitled, Academic promotion and tenure: a user’s guide for junior faculty members
All Issues
Targeted medical therapies for vascular anomalies
T-cell–based therapies for treating relapsed or refractory mantle cell lymphoma
Transplant in ALL: who, when, and how?
Ph− ALL: immunotherapy in upfront treatment
Ph+ ALL: new approaches for upfront therapy
  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal